Mental Health

BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder

BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

2 weeks ago

Health-E Commerce® announces new telehealth collaboration with Rex MD® to support men’s health on FSA Store® and HSA Store®

New collaboration delivers confidential and convenient telehealth services to address erectile dysfunction for men DALLAS, Dec. 11, 2024 /PRNewswire/ --…

2 weeks ago

U.S. Hospitals Report Lower Clinician Turnover, Aon Reports

CHICAGO, Dec. 11, 2024 /PRNewswire/ -- Aon plc (NYSE: AON) reports that more U.S. hospitals are reporting steady or lower employee…

2 weeks ago

EBLM Agrees with Daniel Penny Verdict but Issues a Cautionary Warning

DALLAS, Dec. 11, 2024 /PRNewswire/ -- Every Black Life Matters (EBLM) supports the jury's not guilty verdict for Daniel Penny,…

2 weeks ago

Pomelo Care Publishes Peer-Reviewed Data Demonstrating Significant Impact Of Its Virtual Maternal Health Care Model

Data Shows Pomelo's Virtual Care Model Reduces Total Cost of Maternal Care in Medicaid Population, Lowers NICU and ER Utilization for…

2 weeks ago

New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark’s Center for Evidence-Based Psychiatry

LOS ANGELES, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced today that the Center for…

2 weeks ago

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital

The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.The clinical site is…

2 weeks ago

Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy

– Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose…

2 weeks ago

Reunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting

MORRISTOWN, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment…

2 weeks ago